Browse All

Current Filters

CLEAR FILTER x

TITLE

Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders

Author:Qureshi, Irfan   Beiner, Melissa   Bertz, Richard   Kaplita, Stephen   Yang, Rong   Munivar, Azim   Stock, David   Wirtz, Victoria   Coric, Vladimir   

Session Name:P4: General Neurology: Neuroimmunology  

Topic:General Neurology  

Program Number:P4.013  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  

No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole

Author:Bertz, Richard   Rozakis, Rachel   Donohue, Mary   Sevinsky, Heather   Awsare, Bharat   Kaplita, Stephen   Hussey, Elizabeth   Qureshi, Irfan   Coric, Vladimir   

Session Name:P4: General Neurology: Neuroimmunology  

Topic:General Neurology  

Program Number:P4.014  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Allucent, Cary, NC  

Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults

Author:Awsare, Bharat   Lerner, Jason   Ashbrenner, Eric   Sevinsky, Heather   Bozik, Michael   Dworetzky, Steven   Donahue, Lia   Killingsworth, Randall   Francoeur, Bruno   Qureshi, Irfan   

Session Name:P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P8.007  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Syneos Health, Quebec, QC, Canada  

Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults

Author:Lerner, Jason   Awsare, Bharat   Sevinsky, Heather   Ashbrenner, Eric   Killingsworth, Randall   Kendrick, Racheal   Vereycken, Emiel   Colenbrier, Nigel   Neuray, Caroline   van Mierlo, Pieter   Slater, Jeremy   Wyatt, David   Qureshi, Irfan   Dworetzky, Steven   Bozik, Michael   

Session Name:P8: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Clinical Trials and Outcomes  

Topic:Epilepsy/Clinical Neurophysiology (EEG)  

Program Number:P8.011  

Author Institution:Biohaven Pharmaceuticals, Inc, New Haven, CT  Certara, Inc, Princeton, NJ  Epilog, Clouds of Care NV, Ghent, Belgium  Stratus, Irving, TX  Syneos Health, Quebec, QC, Canada